Vancouver, B.C. and Boston, MA, March 10, 2020 – Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported ongoing market research feedback on the i/BlueTM Imaging System which enables simultaneous viewing of white and blue light images during bladder cancer resection.
Since the American Urological Association (“AUA”) Meeting in May 2019 where leading urologists observed simulated cystoscopy demonstrations, Imagin has continued to collect additional input on its i/Blue Imaging System from physicians in the United States and Canada.
The feedback has focused on the i/Blue’s ability to display side-by-side white and blue light images simultaneously, which would enable real-time cancer visualization during resection. Surgeons would no longer need to switch back and forth between the white and blue light images to perform the surgery as the current method requires. This advanced viewing option has the potential to improve surgical technique.
Jim Huchens, the Company’s President and CEO, commented,
“Since beginning our market research at the AUA meeting last May, we have received valuable positive feedback. We look forward to continuing our conversations with urologists at this year’s AUA meeting as we move closer to delivering the i/Blue’s benefits to the medical community.”
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contact:
Stephen Kilmer
Investor Relations
Telephone: 647-872-4849
Email: [email protected]
Jim Hutchens
President & CEO
Telephone: 833-246-2446
